KRAS and ovarian carcinoma: Finally, to determine if the genes that display altered mRNA expression levels in ovarian cancer patient samples (PIK3CA, TTN, RYR2, KMT2C, KRAS, PTEN, and ARID1A) have any clinical value, we checked the effect of their expression on recurrence and survival of patients with ovarian cancer.